(3-amino-1H-pyrazol-4-yl)-2-pyridinyl-methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (3-amino-1H-pyrazol-4-yl)-2-pyridinyl-methanone
• 英文别名: (5-Amino-1H-pyrazol-4-YL)(pyridin-2-YL)methanone；(5-amino-1H-pyrazol-4-yl)-pyridin-2-ylmethanone
• 化学式: C₉H₈N₄O
• 分子量: 188.189
• InChiKey: DFXNAJDPHAGQPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3-amino-1H-pyrazol-4-yl)-2-pyridinyl-methanone 生成 2-pyridinyl[7-(3-pyridinyl)pyrazolo[1,5-a]pyrimidin-3-yl]methanone
  参考文献：
  名称：

  Aryl and heteroaryl[7-(aryl and

  摘要：

  芳基和杂环芳基[7-(芳基和杂环芳基)吡唑并[1,5-a]嘧啶-3-基]甲酮是新的化合物，对哺乳动物具有抗焦虑、抗抽搐、镇静催眠和骨骼肌松弛作用，并提供了制备这些化合物的新方法。

  公开号：

  US04521422A1
• 作为产物：
  描述：

  5-(2-pyridyl)isoxazole 在 一水合肼 作用下， 反应 18.0h， 生成 (3-amino-1H-pyrazol-4-yl)-2-pyridinyl-methanone
  参考文献：
  名称：

  Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel antiproliferative agents: Exploration of core and headpiece structure–activity relationships

  摘要：

  A novel series of antiproliferative agents containing pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides, selective for p21-deficient cells, were identified by high-throughput screening. Exploration of the SAR relationships in the headpiece, core, and tailpiece is described. Strict steric, positional, and electronic requirements were observed, with a clear preference for both core nitrogens, a thienoyl headpiece, and meta substituted tailpiece. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.116
• 作为试剂：
  描述：

  (3-amino-1H-pyrazol-4-yl)-2-pyridinyl-methanone 、 (E)-3-(二甲基氨基)-1-(吡啶-4-基)丙-2-烯-1-酮 在 (3-amino-1H-pyrazol-4-yl)-2-pyridinyl-methanone 作用下， 生成 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮
  参考文献：
  名称：

  Aryl and heteroaryl[7-(aryl and

  摘要：

  Aryl和heteroaryl [7-(aryl和heteroaryl) pyrazolo [1,5-a] pyrimidin-3-yl] 甲酮是新的化合物，对哺乳动物具有抗焦虑、抗癫痫、镇静催眠和骨骼肌松弛作用，并且提供制备这些化合物的新方法。

  公开号：

  US04521422A1

文献信息

• [EN] 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL) PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES<br/>[FR] 2-PYRIDINYL[7-(PYRIDIN-4-YLE SUBSTITUE)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES
  申请人：DOV PHARMACEUTICAL INC

  公开号：WO2005084439A1

  公开（公告）日：2005-09-15

  The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5­-a]pyrimidin-3-yl]methanones with at least one substituent on the 4-pyridinyl ring having the chemical structure of formula (I): The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula: (I) in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA receptors.

  本发明提供了具有化学结构式(I)的新型2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮，其中4-吡啶基环上至少有一个取代基。该发明还提供了应用化学式(I)的新型2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮的组合物和方法，用于调节GABA和GABA受体生理，以引发哺乳动物主体中的治疗反应，以缓解神经系统或精神障碍，包括中风、头部创伤、癫痫、疼痛、偏头痛、情绪障碍、焦虑、创伤后应激障碍、强迫性障碍、躁狂、双相障碍、精神分裂症、癫痫发作、抽搐、耳鸣、包括阿尔茨海默病、肌萎缩侧索硬化和帕金森病在内的神经退行性疾病、亨廷顿舞蹈症、抑郁症、双相障碍、躁狂、三叉神经痛和其他神经痛、神经痛、高血压、脑缺血、心律失常、肌张力过高、物质滥用、肌阵挛、本体震颤、运动障碍和其他由GABA和/或GABA受体介导的新生儿脑出血、痉挛性瘫痪以及痉挛性瘫痪，以及其他精神和神经障碍的方法。
• Salts And Co-Crystals of Pyrazolopyrimidine Compounds, Compositions Thereof And Methods For Their Production And Use
  申请人：LIPPA S. Arnold

  公开号：US20080045547A1

  公开（公告）日：2008-02-21

  The invention provides pharmaceutically acceptable salts and co-crystals of pyrazolopyrimidine compounds such as zaleplon, indiplon and ocinaplon, processes for their preparation, compositions comprising such salts and co-crystals and methods of using such salts and co-crystals for treating various diseases and conditions.

  这项发明提供了吡唑基嘧啶化合物的药用可接受盐和共晶体，例如扎来普隆、印地普隆和奥西那普隆，以及它们的制备方法、包含这些盐和共晶体的组合物，以及利用这些盐和共晶体治疗各种疾病和症状的方法。
• Method of using substituted pyrazolo [1,5-a] pyrimidines
  申请人：Wang Daniel Yanong

  公开号：US20060063784A1

  公开（公告）日：2006-03-23

  This invention relates to novel methods of use of certain pyrazolo[1,5-a]pyrimidine compounds and the therapeutically acceptable salts thereof. This invention also relates to novel methods of using these compounds as anti-proliferative agents in mammals, including humans.

  这项发明涉及某些吡唑并[1,5-a]嘧啶化合物及其治疗上可接受的盐的新用途方法。该发明还涉及将这些化合物作为抗增殖剂在哺乳动物，包括人类中的新用途方法。
• Substituted pyrazolo[1,5-a] pyrimidines and process for making same
  申请人：Wang Daniel Yanong

  公开号：US20060063785A1

  公开（公告）日：2006-03-23

  This invention relates to novel pyrazolo[1,5-a]pyrimidine compounds and the therapeutically acceptable salts thereof. These compounds are useful as anti-proliferative agents in mammals, including humans.

  这项发明涉及新型吡唑并[1,5-a]嘧啶化合物及其治疗上可接受的盐。这些化合物在哺乳动物，包括人类中作为抗增殖剂是有用的。
• 2-Pyridinyl[7-(substituted-pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones
  申请人：Skolnick Phil

  公开号：US20050277639A1

  公开（公告）日：2005-12-15

  The present invention provides novel 2-pyridinyl[7(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on the 4-pyridinyl ring having the chemical structure of formula I: The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula I in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA receptors.

  本发明提供了一种新型的2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮，其4-吡啶基环上至少有一个取代基，具有化学式I的结构。本发明还提供了使用式I的新型2-吡啶基[7-(吡啶-4-基)吡唑并[1,5-a]嘧啶-3-基]甲酮的组合物和方法，用于调节GABA和GABA受体生理，以引发哺乳动物主体中的治疗反应，以缓解神经系统或精神障碍，包括中风、头部创伤、癫痫、疼痛、偏头痛、情绪障碍、焦虑、创伤后应激障碍、强迫症、躁狂、双相情感障碍、精神分裂症、癫痫发作、惊厥、耳鸣、神经退行性疾病，包括阿尔茨海默病、肌萎缩性侧索硬化症和帕金森病、亨廷顿舞蹈症、抑郁症、双相情感障碍、躁狂、三叉神经痛和其他神经痛、神经病性疼痛、高血压、脑缺血、心律失常、肌强直性疾病、物质滥用、肌阵挛、本体性震颤、运动障碍和其他由GABA和/或GABA受体介导的精神和神经系统障碍，新生儿脑出血和痉挛性瘫痪。